AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03901768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
Study NCT03901768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
Study NCT01926626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moclobemide
Description: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)
Study NCT03212573 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: ERAS protocol includes early oral intake and deambulation and multimodal analgesia
Study NCT03212573 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Oral intake and deambulation 24h after surgery and only intravenous analgesia.
Study NCT01856205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
Description: IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate.
Study NCT03507335 — intervention group
Intervention type: DEVICE
Intervention: chest strap and PPG-device for monitoring the rhythm
Description: chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given as 3mg/m2 IV/PO q8h.
Study NCT01844375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate group
Description: The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
Study NCT01844375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
Study NCT02226185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine hydrochloride
Description: supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
Study NCT02226185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: supplement of placebo two times per day for 2-3 years
Study NCT00002804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00002804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00002804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as 3mg/m2 IV/PO q8h.
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
Study NCT01106092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2036874A vaccine
Description: Intramuscular, single dose
Study NCT01106092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zilbrix™/Hib vaccine
Description: Intramuscular, single dose
Study NCT01106092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, single dose
Study NCT03469869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balanced and sustainable diet
Description: the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.
Study NCT03469869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balanced and sustainable diet
Description: the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.
Study NCT02397018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic umbilical cord blood
Description: Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
Study NCT04555967 — intervention group
Intervention type: DEVICE
Intervention: SAPIEN 3 Ultra System
Description: Transcatheter aortic valve implantation
Study NCT01407653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
Study NCT01407653 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual care
Description: Classical care
Study NCT02434471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory-triggered T1w DISCO LAVA
Description: The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase
Study NCT01413347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pillow
Description: bronchoscopic confirmation of double-lumen tube position with a head on a pillow
Study NCT01413347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neutral
Description: bronchoscopic confirmation of double-lumen tube position in neutral position of a head
Study NCT01850576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Description: STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
Study NCT00002804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT02921386 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Study NCT01892722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Administration once weekly via i.m. injections.
Study NCT01892722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.
Study NCT01892722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsule required for double-dummy masking to blind formulations.
Study NCT01892722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo i.m. injection
Description: Matching placebo i.m. injection required for double-dummy masking to blind formulations.
Study NCT01707992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered as per the dose and schedule specified in the respective arms.
Study NCT00002804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00002804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT01585259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anfibatide
Description: Snake venom
Study NCT00642889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study NCT00642889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02333864 — intervention group
Intervention type: DEVICE
Intervention: POGO® BGMS
Description: SMBG
Study NCT01238627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Sublingual Tablet Mint (NSTM)
Description: A single dose of an experimental NSTM, with a 36-hour washout between visits
Study NCT01238627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Tablet
Description: A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
Study NCT04043624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
Study NCT04043624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV bolus of saline, followed by continuous infusion of saline
Study NCT02384057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training program
Description: 1000 minutes of computerized cognitive rehabilitation with C8 sciences program
Study NCT02384057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cognitive rehabilitation
Description: Same amount of conventional cognitive rehabilitation
Study NCT01643031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
Study NCT01707992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
Study NCT01707992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
Study NCT01260558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-Permanent-Polymer Eluting Stent
Description: due randomization sirolimus-permanent-polymer eluting stent was implanted
Study NCT01260558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-Polymer-free Eluting Stent
Description: due randomization sirolimus-polymer-free eluting stent was implanted
Study NCT03404778 — intervention group
Intervention type: DEVICE
Intervention: Biomet Comprehensive Reverse Shoulder
Description: Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg PO q 12h x 7d post op
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30mg IV once at end of hysterectomy procedure
Study NCT02738671 — intervention group
Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Study NCT04429022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracervical block with ropivacaine
Description: 0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
Study NCT04429022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites
Description: 0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1mg IV PRN q3h, post op, while inpatient
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1mg IV PRN q3h, post op, while inpatient
Study NCT04429022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: To be discharged home with: 12 tabs of 5mg PRN q4h
Study NCT02519660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Tetracaine patch
Study NCT02519660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine cream
Study NCT04590001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
Study NCT03596346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed ingredient (RI)
Description: 2 snack bars daily containing 10 g of RI each.
Study NCT03596346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product without added RI
Description: 2 snack bars daily containing 0 g of RI.
Study NCT01077765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eutrophill
Description: Polyacrylamide Hydrogel
Study NCT00369031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Immunodeficiency Virus glycoprotein 140 (vaccine)
Description: Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
Study NCT00369031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant
Description: Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
Study NCT00369031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Labile Toxin mutant LTK63 adjuvant
Description: Labile Toxin mutant LTK63 adjuvant alone
Study NCT01436721 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Surgicel® absorbable Haemostat
Description: The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
Study NCT03283631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRvIII-CARs
Description: Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
Study NCT05480969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart failure educational intervention
Description: Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
Study NCT03521791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-155
Description: PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac
Study NCT03521791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac
Study NCT03313960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza plus One Drop | Premium
Description: Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).
Study NCT03313960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: One Drop | Premium
Description: Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).
Study NCT00650611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.
Study NCT00650611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.
Study NCT02664155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Direct Oral Anticoagulant
Study NCT02664155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Direct Oral Anticoagulant
Study NCT02664155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Standard Of Care
Study NCT02664155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA
Description: Standard Of Care